SlideShare uma empresa Scribd logo
1 de 16
DIGOXIN TOXICITY
By Dr.VIJAY
Department of Pharmacology
DIGOXIN
 SOURCE:
 STRUCTURE:
 MECHANISM OF ACTION:
DIGOXIN TOXICITY
PREDISPOSING FACTORS:
 Age
 Hypokalemia
 Hypercalcemia
 Impaired renal function
 Cor pulmonale
 Cardiac status
 Hormones
 Inappropriate use
CAUSES :
 Drug interactions causing increase in digoxin
levels:
 Hypokalemia:
 Calcium salts:
 Drugs which displace digoxin from
protien binding sites:
 Catecholamines,Sch:
Manifestations of Toxicity
 CARDIAC TOXICITY:
Most common manifestation:
PAROXYSMAL ATRIAL
TACHYCARDIA WITH BLOCK
Others: Multifocal extrasystoles & bigeminy
AV block
Sinoatrial arrest
VT and VF
 GASTROINTESTINAL TOXICITY:
 NEUROLOGICAL TOXICITY:
 MISCELLANEOUS TOXICITY:skin
rash,eosinophilia,gynecomastia.
 TOXICITY in Pregnancy:
DIFFERENTIAL DIAGNOSIS
 CHF and Pulmonary edema
 Heart Block
 Beta blocker toxicity
 VT and VF
 Low K and high K level
 Low Mg and high Ca levels.
DIAGNOSIS
 Symptoms and signs:
 Past h/o digitalization:
 ECG:
 Electrolyte and Renal status:
 Plasma digoxin level:0.5-2ng/ml:
After acute ingestion digoxin level do not
necessarily correlate with toxicity.
T1/2 of digoxin is reduced to 10-12hrs after
acute ingestion.
 Plasma digoxin levels should be
measured at least 6 hours after the last
dose, since this is the time required for
attainment of the steady state.
 An extremely rapid radioimmunoassay for digoxin
on the use of iodine 125-labelled digoxin and of a gel
equilibration technique for the separation of antibody-
bound and free digoxin.
 Endogenous Digoxin Like
Immunoreactive Substances {DLIS}
seen in neonates,renal insufficiency,liver
disease,SAH,CHF,diabetes.
TREATMENT OF TOXICITY
 Stop digoxin and diuretics:
 GIT decontamination:
 Decreasing absorption:
 Estimate serum potassium:
 Bradycardia:
 Mild toxicity:
Potassium salts:5-7.5g of KCl
Serious arrhythmias:40mEq of KCl in 500ml
of 5% glucose IV OVER 2-4 hrs.
C/I to use of potassium:
 Supraventricular tachyarrhythmias:
Propranolol :oral dose of 10-40mg every
6hrs /IV .5-1-1mg.
 Ventricular tachycardia:
Lignocaine:1-2mg /kg IV repeat in 20-
30mins.
Phenytoin: IV:250mg well diluted over 3-
5min.
 Severe toxicity:DIGIBIND
Antidigoxin antibodies:
Source:
MOA:
Molecular weight:
T1/2:
Indications:
Life threatening arrhythmias
Hemodynamic instability
Severe bradycardia
Serum potassium level:
Plasma digoxin level:
Time taken for complete response:
 Dosing of Digibind:
Vials of digibind=digoxin level[ng/ml]x wt[kg]
100
1Vial of Digibind=40mg
= neutralizes 0.6mg of digoxin.
 Side effects of Digibind:
Allergic reactions
Exacerbation of CHF
Hypokalemia
Plasma digoxin level unreliable
after digibind is given.
Increased ventricular response
to atrial fibrillation and flutter.
 CONTRAINDICATIONS:Allergic to sheep
protien, papain, papaya extracts.

Mais conteúdo relacionado

Mais procurados (20)

Ceftriaxone drug profile, drug club ppt
Ceftriaxone drug profile, drug club pptCeftriaxone drug profile, drug club ppt
Ceftriaxone drug profile, drug club ppt
 
Aminophylline
AminophyllineAminophylline
Aminophylline
 
Atropine
AtropineAtropine
Atropine
 
Cardiac glycosides
Cardiac glycosidesCardiac glycosides
Cardiac glycosides
 
Dopamine & dobutamine
Dopamine & dobutamineDopamine & dobutamine
Dopamine & dobutamine
 
Thiazide diuretics (chlorothiazide)
Thiazide diuretics (chlorothiazide)Thiazide diuretics (chlorothiazide)
Thiazide diuretics (chlorothiazide)
 
Diuretics...
Diuretics...Diuretics...
Diuretics...
 
Digoxin
DigoxinDigoxin
Digoxin
 
Digoxin and its Toxicity
Digoxin and its ToxicityDigoxin and its Toxicity
Digoxin and its Toxicity
 
Thrombolytics or Fibrinolytics
Thrombolytics or FibrinolyticsThrombolytics or Fibrinolytics
Thrombolytics or Fibrinolytics
 
Digoxin
DigoxinDigoxin
Digoxin
 
Calcium channel blockers nikku
Calcium channel blockers nikkuCalcium channel blockers nikku
Calcium channel blockers nikku
 
Heparin
HeparinHeparin
Heparin
 
Potassium sparing diuretics
Potassium sparing diureticsPotassium sparing diuretics
Potassium sparing diuretics
 
Digoxin- GLYCOSIDE
Digoxin- GLYCOSIDEDigoxin- GLYCOSIDE
Digoxin- GLYCOSIDE
 
Aspirin in Myocardial Infarction by Pharm Jimmy Aiden
Aspirin in Myocardial Infarction by Pharm Jimmy AidenAspirin in Myocardial Infarction by Pharm Jimmy Aiden
Aspirin in Myocardial Infarction by Pharm Jimmy Aiden
 
Digitalis nikku ppt
Digitalis nikku pptDigitalis nikku ppt
Digitalis nikku ppt
 
thiazides
 thiazides  thiazides
thiazides
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
 
Adrenalin
AdrenalinAdrenalin
Adrenalin
 

Semelhante a Digitalis toxicity vijay

Diabetic emergencies
Diabetic emergenciesDiabetic emergencies
Diabetic emergenciesRichardKeshi
 
Endocrine hypertension
Endocrine hypertensionEndocrine hypertension
Endocrine hypertensionNaveen Kumar
 
CCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTURECCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTUREADAMAGABA
 
Congenital adrenal hyperplasia
Congenital  adrenal hyperplasiaCongenital  adrenal hyperplasia
Congenital adrenal hyperplasiaShiva Polisetty
 
Cardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecteCardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affectewajidullah9551
 
Endocrine disorders of adrenal gland
Endocrine disorders of adrenal glandEndocrine disorders of adrenal gland
Endocrine disorders of adrenal glandSubhasish Deb
 
Diabetic ketoacidosis
Diabetic ketoacidosisDiabetic ketoacidosis
Diabetic ketoacidosisSonam Yeshi
 
Diabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptxDiabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptxHafizuddinSalim1
 
MINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASEMINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASERaheel Ahmed
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusinternalmed
 
Approach to a child with jaundice
Approach to a child with jaundice Approach to a child with jaundice
Approach to a child with jaundice Bala Sankar
 
juvinile diabetes mellitus clinical features and investigations
 juvinile diabetes mellitus clinical features and investigations juvinile diabetes mellitus clinical features and investigations
juvinile diabetes mellitus clinical features and investigationsShiva Polisetty
 
Endocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney diseaseEndocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney diseaseDr. Lala Shourav Das
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementMedicineAndFamily
 
Nephrotic syndrome final
Nephrotic syndrome finalNephrotic syndrome final
Nephrotic syndrome finalakilav99
 

Semelhante a Digitalis toxicity vijay (20)

Diabetic emergencies
Diabetic emergenciesDiabetic emergencies
Diabetic emergencies
 
Seco dka
Seco dkaSeco dka
Seco dka
 
Endocrine hypertension
Endocrine hypertensionEndocrine hypertension
Endocrine hypertension
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
CCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTURECCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTURE
 
Congenital adrenal hyperplasia
Congenital  adrenal hyperplasiaCongenital  adrenal hyperplasia
Congenital adrenal hyperplasia
 
Cardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecteCardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecte
 
Endocrine disorders of adrenal gland
Endocrine disorders of adrenal glandEndocrine disorders of adrenal gland
Endocrine disorders of adrenal gland
 
Diabetic ketoacidosis
Diabetic ketoacidosisDiabetic ketoacidosis
Diabetic ketoacidosis
 
Adrenocortical disorders
Adrenocortical disordersAdrenocortical disorders
Adrenocortical disorders
 
Diabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptxDiabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptx
 
Digoxin
DigoxinDigoxin
Digoxin
 
MINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASEMINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASE
 
43651
4365143651
43651
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
 
Approach to a child with jaundice
Approach to a child with jaundice Approach to a child with jaundice
Approach to a child with jaundice
 
juvinile diabetes mellitus clinical features and investigations
 juvinile diabetes mellitus clinical features and investigations juvinile diabetes mellitus clinical features and investigations
juvinile diabetes mellitus clinical features and investigations
 
Endocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney diseaseEndocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney disease
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental management
 
Nephrotic syndrome final
Nephrotic syndrome finalNephrotic syndrome final
Nephrotic syndrome final
 

Mais de yerroju vijay

IA-English-Life QP.pdf
IA-English-Life QP.pdfIA-English-Life QP.pdf
IA-English-Life QP.pdfyerroju vijay
 
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...yerroju vijay
 
Vegf inhibitors for ophthalmic use
Vegf inhibitors  for ophthalmic useVegf inhibitors  for ophthalmic use
Vegf inhibitors for ophthalmic useyerroju vijay
 
TYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSTYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSyerroju vijay
 

Mais de yerroju vijay (6)

IA-English-Life QP.pdf
IA-English-Life QP.pdfIA-English-Life QP.pdf
IA-English-Life QP.pdf
 
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
 
Vegf inhibitors for ophthalmic use
Vegf inhibitors  for ophthalmic useVegf inhibitors  for ophthalmic use
Vegf inhibitors for ophthalmic use
 
Torsades de-pointes
Torsades de-pointesTorsades de-pointes
Torsades de-pointes
 
TYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSTYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORS
 
Stem cell therapy
Stem cell therapyStem cell therapy
Stem cell therapy
 

Último

Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxContemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxRoyAbrique
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Sapana Sha
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Krashi Coaching
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 

Último (20)

Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxContemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 

Digitalis toxicity vijay

  • 3.
  • 4.
  • 5. DIGOXIN TOXICITY PREDISPOSING FACTORS:  Age  Hypokalemia  Hypercalcemia  Impaired renal function  Cor pulmonale  Cardiac status  Hormones  Inappropriate use CAUSES :
  • 6.  Drug interactions causing increase in digoxin levels:  Hypokalemia:  Calcium salts:  Drugs which displace digoxin from protien binding sites:  Catecholamines,Sch:
  • 7. Manifestations of Toxicity  CARDIAC TOXICITY: Most common manifestation: PAROXYSMAL ATRIAL TACHYCARDIA WITH BLOCK Others: Multifocal extrasystoles & bigeminy AV block Sinoatrial arrest VT and VF
  • 8.  GASTROINTESTINAL TOXICITY:  NEUROLOGICAL TOXICITY:  MISCELLANEOUS TOXICITY:skin rash,eosinophilia,gynecomastia.  TOXICITY in Pregnancy:
  • 9. DIFFERENTIAL DIAGNOSIS  CHF and Pulmonary edema  Heart Block  Beta blocker toxicity  VT and VF  Low K and high K level  Low Mg and high Ca levels.
  • 10. DIAGNOSIS  Symptoms and signs:  Past h/o digitalization:  ECG:  Electrolyte and Renal status:  Plasma digoxin level:0.5-2ng/ml: After acute ingestion digoxin level do not necessarily correlate with toxicity. T1/2 of digoxin is reduced to 10-12hrs after acute ingestion.
  • 11.  Plasma digoxin levels should be measured at least 6 hours after the last dose, since this is the time required for attainment of the steady state.  An extremely rapid radioimmunoassay for digoxin on the use of iodine 125-labelled digoxin and of a gel equilibration technique for the separation of antibody- bound and free digoxin.  Endogenous Digoxin Like Immunoreactive Substances {DLIS} seen in neonates,renal insufficiency,liver disease,SAH,CHF,diabetes.
  • 12. TREATMENT OF TOXICITY  Stop digoxin and diuretics:  GIT decontamination:  Decreasing absorption:  Estimate serum potassium:  Bradycardia:  Mild toxicity: Potassium salts:5-7.5g of KCl Serious arrhythmias:40mEq of KCl in 500ml of 5% glucose IV OVER 2-4 hrs. C/I to use of potassium:
  • 13.  Supraventricular tachyarrhythmias: Propranolol :oral dose of 10-40mg every 6hrs /IV .5-1-1mg.  Ventricular tachycardia: Lignocaine:1-2mg /kg IV repeat in 20- 30mins. Phenytoin: IV:250mg well diluted over 3- 5min.
  • 14.  Severe toxicity:DIGIBIND Antidigoxin antibodies: Source: MOA: Molecular weight: T1/2: Indications: Life threatening arrhythmias Hemodynamic instability Severe bradycardia Serum potassium level: Plasma digoxin level: Time taken for complete response:
  • 15.  Dosing of Digibind: Vials of digibind=digoxin level[ng/ml]x wt[kg] 100 1Vial of Digibind=40mg = neutralizes 0.6mg of digoxin.
  • 16.  Side effects of Digibind: Allergic reactions Exacerbation of CHF Hypokalemia Plasma digoxin level unreliable after digibind is given. Increased ventricular response to atrial fibrillation and flutter.  CONTRAINDICATIONS:Allergic to sheep protien, papain, papaya extracts.